2. Search Result
Search Result
Results for "

CRC cancer

" in MedChemExpress (MCE) Product Catalog:

93

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dye

5

Peptides

6

Inhibitory Antibodies

12

Natural
Products

2

Isotope-Labeled Compounds

1

Antibodies

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N5014
    Liensinine perchlorate
    Maximum Cited Publications
    12 Publications Verification

    		 Apoptosis Cardiovascular Disease Inflammation/Immunology Cancer
    Liensinine Perchlorate is a constituent of?Nelumbo nucifera?Gaertn, with ani-hypertension and anti-cancer activities. Liensinine Perchlorate induces?colorectal cancer (CRC) cell apoptosis .
    Liensinine perchlorate
  • HY-155068
    FC-116

    		Microtubule/Tubulin Reactive Oxygen Species (ROS) Apoptosis PERK Eukaryotic Initiation Factor (eIF) IRE1 Cancer
    FC-11 is a tubulin inhibitor. FC-116 inhibits the proliferation of colorectal cancer (CRC) cells, with IC50 values of 4.52 nM for HCT116 cells and 18.69 nM for CT26 cells. FC-11 can induce ER stress to generate excess ROS, leading to mitochondrial damage, thereby promoting apoptosis in colorectal cancer (CRC) cells by targeting microtubules. FC-116 exerts potent anti-tumor effects in vivo. FC-11 can be used for the study of colorectal cancer .
    FC-116
  • HY-123772
    CDK5 inhibitor 20-223
    1 Publications Verification

    CP668863

    		 CDK Cancer
    CDK5 inhibitor 20-223 is a potent CDK2 and CDK5 inhibitor with IC50s of 6.0 and 8.8 nM, respectively. CDK5 inhibitor 20-223 is an effective anti-colorectal cancer (CRC) agent .
    CDK5 inhibitor 20-223
  • HY-139065
    AMPC

    		Others Cancer
    AMPC is a potent and effective TFF3 inhibitor. AMPC inhibits cell proliferation, survival, oncogenicity, and CSC-like behaviour in TFF3-positive CMS4 CRC cells. AMPC acts as a potential anti-cancer agent alone or in combination with 5-FU, and can be used for cancer research .
    AMPC
  • HY-160493
    PTK7/β-catenin-IN-6

    		Wnt β-catenin Cancer
    PTK7/β-catenin-IN-6 (Compound 03653) is an inhibitor for PTK7/β-catenin interaction, which inhibits the Wnt signaling pathway, and exhibits an anticancer activity against colorectal cancer (CRC) .
    PTK7/β-catenin-IN-6
  • HY-175753
    Z17544625

    		Others Cancer
    Z17544625 is a Fascin inhibitor. Z17544625 has a strong binding capacity to fascin and inhibits Actin bundling. Z17544625 significantly reduces proliferation and impairs migration of CRC cells. Z17544625 can be used for cancer, especially colorectal cancer (CRC) research .
    Z17544625
  • HY-175762
    Z118298144

    		Others Cancer
    Z118298144 is a Fascin inhibitor. Z118298144 has a strong binding capacity to fascin and inhibits Actin bundling. Z118298144 significantly reduces proliferation and impairs migration of CRC cells. Z118298144 can be used for cancer, especially colorectal cancer (CRC) research .
    Z118298144
  • HY-108695
    Enterodiol

    		Apoptosis Endogenous Metabolite Cancer
    Enterodiol is transformed by human intestinal bacteria from lignans contained in various whole-grain cereals, nuts, legumes, flaxseed, and vegetables. Enterodiol has an apoptotic effect in colorectal cancer (CRC) cells. Anti-cancer activities .
    Enterodiol
  • HY-P991719
    Tambotatug

    YL201 antibody

    		 CD276/B7-H3 Inflammation/Immunology Cancer
    Tambotatug is a humanized IgG1κ monoclonal antibody inhibitor targeting CD276/B7-H3. Tambotatug has antitumor activity. Tambotatug can be used for tumor immunotherapy like colorectal cancer (CRC) research .
    Tambotatug
  • HY-108433
    CPT2

    Carnitine palmitoyltransferase 2

    		 Apoptosis MDM-2/p53 Metabolic Disease Cancer
    CPT2 (Carnitine palmitoyltransferase 2), an enzyme that participates in fatty acid oxidation, also is a colorectal cancer (CRC) prognostic biomarker. CPT2 overexpression can activate p-p53 to increase p53 expression, thereby inhibiting tumor proliferation and promoting apoptosis. CPT2 deficiency results in the most common inherited disorder of long-chain fatty acid oxidation affecting skeletal muscle. Downregulation of CPT2 is also highly correlated with the progression of various cancers and has potential for cancer research .
    CPT2
  • HY-172807
    p38α-IN-9

    		p38 MAPK MAPKAPK2 (MK2) CDK Wee1 Cancer
    p38α-IN-9 (Compound 2015) is a p38α inhibitor and blocks p38α’s enzymatic activity with an IC50 lower than 20 nM. p38α-IN-9 inhibits MK2 T334 phosphorylation. p38α-IN-9 activates Cdc25b and Cdc25c and simultaneously inactivates Wee1, leading to mitotic catastrophe, aneuploidy or polyploidy and DNA damage. p38α-IN-9 Inhibits colorectal cancer (CRC) metastasis .
    p38α-IN-9
  • HY-P99406
    Petosemtamab

    MCLA 158

    		 EGFR Cancer
    Petosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .
    Petosemtamab
  • HY-P99613
    Favezelimab

    MK-4280

    		 LAG-3 Cancer
    Favezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3. Favezelimab blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research in combination with the PD-L1 inhibitor Pembrolizumab (HY-P9902). Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
    Favezelimab
  • HY-B0294
    Flubendazole
    5+ Cited Publications

    		 Parasite Microtubule/Tubulin STAT MDM-2/p53 Apoptosis Autophagy Infection Cancer
    Flubendazole is an anthelmintic drug based on altering microtubule structure, inhibition of tubulin polymerization and disruption of microtubule function. Flubendazole induces apoptosis in human colorectal cancer (CRC) by blocking the STAT3 signaling axis and activation of autophagy. Flubendazole induces P53 expression and reduced Cyclin B1 and p-cdc2 expression. Flubendazole is an antitumor agent. Flubendazole can be used for worm and intestinal parasites .
    Flubendazole
  • HY-168736
    CRC-IN-1

    		Drug Derivative Cancer
    CRC-IN-1 (compound (-)-15h) is a potent anti-colorectal cancer (CRC) agent, as well as a derivative of the anticancer agent Evodiamine (HY-N0114) .
    CRC-IN-1
  • HY-B0294R
    Flubendazole (Standard)

    		Reference Standards Parasite Microtubule/Tubulin STAT MDM-2/p53 Apoptosis Autophagy Infection Cancer
    Flubendazole (Standard) is the analytical standard of Flubendazole. This product is intended for research and analytical applications. Flubendazole is an anthelmintic drug based on altering microtubule structure, inhibition of tubulin polymerization and disruption of microtubule function. Flubendazole induces apoptosis in human colorectal cancer (CRC) by blocking the STAT3 signaling axis and activation of autophagy. Flubendazole induces P53 expression and reduced Cyclin B1 and p-cdc2 expression. Flubendazole is an antitumor agent. Flubendazole can be used for worm and intestinal parasites .
    Flubendazole (Standard)
  • HY-151939
    BLM-IN-2

    		DNA/RNA Synthesis Apoptosis Cancer
    BLM-IN-2 is a Bloom's Syndrome Protein (BLM) inhibitor with an IC50 value of 0.8 μM. BLM-IN-2 effectively suppresses the proliferation, invasion, cell cycle arrest and apoptosis of CRC cells. BLM-IN-2 can be used for the reserarch of colorectal cancer (CRC) .
    BLM-IN-2
  • HY-170306
    LZ9

    		CDK Cancer
    LZ9 is a ATP-competitive CDK1 and CDK2 inhibitor. LZ9 has the potential for the research of colorectal cancer (CRC) .
    LZ9
  • HY-145120
    Mosperafenib

    RG6344; RO7276389; B-Raf IN 2

    		 Raf Cancer
    BRAF inhibitor. RG6344 can be used for the study of BRAF V600-mutant solid tumors, such as colorectal cancer (CRC) .
    Mosperafenib
  • HY-163828
    PPA24

    		Apoptosis Phosphatase c-Myc GSK-3 ERK Reactive Oxygen Species (ROS) Cancer
    PPA24 is a PP2A activator with a KD of 8.465 μM for PP2ACα. PPA24 induces cancer cell death via apoptosis. PP2ACα induces ROS generation and decreases the level of c-Myc expression. PPA24 can be used to study colorectal cancer (CRC), Folinic acid (HY-17556), 5-Fluorouracil (HY-90006), and Oxaliplatin (HY-17371) (FOLFOX)-resistant CRC, and melanoma cancer .
    PPA24
  • HY-N11777
    (−)-N-Hydroxyapiosporamide

    NHAP

    		 NF-κB Cancer
    (−)-N-Hydroxyapiosporamide (NHAP), an alkaloid, is an NF-κB inhibitor with potent antitumor activity in vitro and in vivo. (−)-N-Hydroxyapiosporamide can be used for the research of colorectal cancer (CRC) .
    (−)-N-Hydroxyapiosporamide
  • HY-B0008A
    Sulindac sodium

    MK-231 sodium

    		 NF-κB PD-1/PD-L1 Infection Inflammation/Immunology Cancer
    Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer .
    Sulindac sodium
  • HY-B0008
    Sulindac

    MK-231

    		 NF-κB PD-1/PD-L1 Inflammation/Immunology Cancer
    Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer .
    Sulindac
  • HY-136358
    LDN-211904

    		Ephrin Receptor Cancer
    LDN-211904 is a potent and reversible EphB3 inhibitor with an IC50 of 79 nM. LDN-211904 shows good metabolic stability in mouse liver microsomes. LDN-211904 with cetuximab could be effective in inhibiting STAT3-activated colorectal cancer (CRC) stemness and Cetuximab (HY-P9905) resistance in CRC .
    LDN-211904
  • HY-153214
    YW2036

    		Wnt β-catenin Cancer
    YW2036 (compound 2a) is a potent Wnt/β-Catenin signaling pathway inhibitor with an IC50 value of 637 nM. YW2036 can be used in research of colorectal cancer (CRC) .
    YW2036
  • HY-178921
    HJ-4

    		Drug Derivative Apoptosis Cancer
    HJ-4 is a Piperine (HY-N0144) derivative. HJ-4 potently inhibits the proliferation of CRC cells by dose-dependently reducing colony formation and DNA synthesis. HJ-4 markedly suppresses the adhesion, migration, invasion and induces apoptosis of CRC cells. HJ-4 demonstrates anti-tumor efficacy in chicken embryo chorioallantoic membrane (CAM) model implanted with HCT116/SW480 tumor spheroids. HJ-4 can be used for the study of colorectal cancer (CRC) .
    HJ-4
  • HY-P991635
    PF-07329640

    		TNF Receptor Cancer
    PF-07329640 is a humanized monoclonal antibody inhibitor targeting TNFRSF3. PF-07329640 can be used for advanced/metastatic solid tumors like non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) research .
    PF-07329640
  • HY-107460
    LDN-211904 oxalate
    1 Publications Verification

    		 Ephrin Receptor Cancer
    LDN-211904 oxalate is a potent and reversible EphB3 inhibitor with an IC50 of 79 nM. LDN-211904 oxalate shows good metabolic stability in mouse liver microsomes. LDN-211904 oxalate with Cetuximab (HY-P9905) could be effective in inhibiting STAT3-activated colorectal cancer (CRC) stemness and Cetuximab resistance in CRC .
    LDN-211904 oxalate
  • HY-145292
    TNIK-IN-2

    		Ser/Thr Protease Cancer
    TNIK-IN-2 is a Traf2- and Nck-interacting protein kinase (TNIK) inhibitor, with an IC50 of 1.3337 μM. TNIK-IN-2 can be used for the study of colorectal cancer (CRC) .
    TNIK-IN-2
  • HY-175783
    MM927

    		Apoptosis Cancer
    MM927 is a potent NVL inhibitor, with an IC50 of 0.053 μM. MM927 blocks 60S ribosomal subunit biogenesis in the nucleolus. MM927 induces half-mer polysomes, cell cycle arrest at G1/S and G2/M and apoptosis in cells. MM927 demonstrates antitumor efficacy in MOLM-13 AML and HCT116 CRC xenograft models. MM927 can be used for the study of cancers such as acute myeloid leukemia (AML) and colorectal cancer (CRC) .
    MM927
  • HY-153833
    PDS-0330

    KVA-E-23A

    		 Gap Junction Protein Cancer
    PDS-0330 is a specific and potent Claudin-1 inhibitor. PDS-0330 interferes with claudin-1/Src association and inhibits colorectal cancer (CRC) progression and metastasis .
    PDS-0330
  • HY-136541
    YB-0158
    2 Publications Verification

    Wnt pathway inhibitor 2

    		 Wnt Apoptosis Cancer
    YB-0158 (Wnt pathway inhibitor 2) is a reverse-turn peptidomimetic and a potent colorectal cancer stem cell (CSC) targeting agent. YB-0158 disrupts Sam68-Src interactions and induces apoptosis in CRC cells. Anti-cancer activities .
    YB-0158
  • HY-108695B
    (±)-Enterodiol

    		Apoptosis Endogenous Metabolite Cancer
    (±)-Enterodiol is the racemate of Enterodiol (HY-108695). Enterodiol is transformed by human intestinal bacteria from lignans contained in various whole-grain cereals, nuts, legumes, flaxseed, and vegetables. Enterodiol has an apoptotic effect in colorectal cancer (CRC) cells. Enterodiol has anti-cancer activities .
    (±)-Enterodiol
  • HY-B0008R
    Sulindac (Standard)

    MK-231 (Standard)

    		 Reference Standards NF-κB PD-1/PD-L1 Inflammation/Immunology Cancer
    Sulindac (Standard) is the analytical standard of Sulindac. This product is intended for research and analytical applications. Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer .
    Sulindac (Standard)
  • HY-162516
    DBI-2

    		AMPK Mitochondrial Metabolism Cancer
    DBI-2 is an AMPK activator targeting mitochondrial complex I. DBI-2 disrupts the OXPHOS process, and reduces ATP generation in mitochondria. DBI-2 inhibits the proliferation of colorectal cancer (CRC) cells .
    DBI-2
  • HY-172537
    Indolimine-214

    		DNA/RNA Synthesis Inflammation/Immunology Cancer
    Indolimine-214 is a metabolite of M. morganii Indolimine-214 increases the level of γH2AX in HeLa cells. Indolimine-214 can be used in the study of inflammatory bowel disease (IBD) and colorectal cancer (CRC) .
    Indolimine-214
  • HY-P1201
    Cyclosomatostatin
    1 Publications Verification

    		 Somatostatin Receptor Cancer
    Cyclosomatostatin is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .
    Cyclosomatostatin
  • HY-119261
    Ruboxyl

    		Antibiotic Cancer
    Ruboxyl is an anthracycline antibiotic with antitumor activity. Ruboxyl inhibits colorectal cancer (CRC) liver metastasis in mice by 84%, suppresses B16 melanoma growth, and increases the survival rate of mice with L1210 or L5178Y leukemia .
    Ruboxyl
  • HY-P10944
    Unlabeled FXX489

    NNS309

    		 FAP Cancer
    Unlabeled FXX489 (NNS309) is a fibroblast activation protein (FAP)-targeting ligand. Unlabeled FXX489 can be labeled with 68Ga and 177Lu and shows anticancer effects. Unlabeled FXX489 can be used for the study of pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), breast cancer (BC), and colorectal cancer (CRC) .
    Unlabeled FXX489
  • HY-P1201A
    Cyclosomatostatin TFA

    		Somatostatin Receptor Cancer
    Cyclosomatostatin TFA is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin TFA can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .
    Cyclosomatostatin TFA
  • HY-169422
    GSK4418959

    IDE275

    		 DNA/RNA Synthesis Cancer
    GSK4418959 (IDE275) is a selective, reversible and orally active WRN helicase inhibitor. GSK4418959 shows >10,000-fold selectivity over other helicases. GSK4418959 inhibits ATPase and DNA unwinding functions in an ATP-competitive manner. GSK4418959 can be used for the study of microsatellite instability-high (MSI-H) cancer, such as colorectal cancer (CRC) and endometrial cancer (EC) .
    GSK4418959
  • HY-114491A
    Rineterkib hydrochloride

    		ERK Raf Cancer
    Rineterkib hydrochloride (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF .
    Rineterkib hydrochloride
  • HY-114491
    Rineterkib

    		ERK Raf Cancer
    Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF .
    Rineterkib
  • HY-N3913
    Furowanin A

    		STAT Bcl-2 Family Cancer
    Furowanin A is a flavonoid with anti-neoplastic effects. Furowanin A inhibits STAT3/Mcl-1 axis to suppress proliferation, block cell cycle progression, induce apoptosis and promote autophagy. Furowanin A potently inhibits colorectal cancer (CRC) cells .
    Furowanin A
  • HY-P6083
    RTSPSSR

    		Biochemical Assay Reagents Others Cancer
    RTSPSSR is synthesized peptide, which binds specifically to claudin-1 and visulizes the CRC tumor in mice, through near-infrared fluorescence imaging .
    RTSPSSR
  • HY-158711
    STING agonist-38

    		STING Cancer
    STING agonist-38 (compound 58) is a potent agonist of STING, with the EC50 of 0.05 μM in THP1 cells. STING agonist-38 has certain oral bioactivity .
    STING agonist-38
  • HY-161140
    PI3Kα-IN-16

    		PI3K Wnt Cancer
    PI3Kα-IN-16 (Z86) is a novel PI3Kα inhibitor with an IC50 value of 4.28 μM. PI3Kα-IN-16 has potent inhibitory efficiency on PI3K-mediated CRCs growth and migration. PI3Kα-IN-16 also inhibits the Wnt signaling pathway .
    PI3Kα-IN-16
  • HY-N3001
    Isolinderalactone

    		STAT VEGFR Bcl-2 Family Survivin IAP NF-κB Apoptosis Caspase Neurological Disease Inflammation/Immunology Cancer
    Isolinderalactone is a sesquiterpene that exhibits anti-cancer, anti-inflammatory, and neuroprotective effects. Isolinderalactone inhibits VEGF expression and tyrosine phosphorylation of VEGFR2. Isolinderalactone decreases viability and induces apoptosis in U-87 glioblastoma (GBM) cells and colorectal cancer (CRC) cells. Isolinderalactone induces G2/M phase cell cycle arrest, ROS generation, pJNK/p38 MAPK activation, in colorectal cancer (CRC) cells. Isolinderalactone blocks LPS (HY-D1056)-induced NF-κB activation while activating Nrf2-HMOX1 signaling in RAW264.7 macrophages. Isolinderalactone improves cognitive dysfunction in APP/PS1 mice. Isolinderalactone can be used for the study of Glioblastoma multiforme (GBM), colorectal cancer, Alzheimer’s disease and acute lung injury .
    Isolinderalactone
  • HY-175698
    Ferroptosis inducer-9

    		Ferroptosis Microtubule/Tubulin COX Glutathione Peroxidase Cancer
    Ferroptosis inducer-9 is a ferroptosis inducer and colchicine site tubulin polymerization inhibitor. Ferroptosis inducer-9 inhibits MCF-7 cell growth with an IC50 of 14 nM and inhibits [ 3H]colchicine binding. Ferroptosis inducer-9 reduces expression of GPX4 and FTH, increases COX2 and ACSL4, lowers GSH, NADP+, and NADPH levels, increases LPO, MDA, and Fe(II) levels, and decreases SOD concentrations. Ferroptosis inducer-9 demonstrates significant anti-tumor efficacy in HCT116 CRC xenograft model. Ferroptosis inducer-9 can be used for the study of triple negative breast cancer (TNBC) and colorectal cancer (CRC) .
    Ferroptosis inducer-9
  • HY-108695BR
    (±)-Enterodiol (Standard)

    		Reference Standards Apoptosis Endogenous Metabolite Cancer
    (±)-Enterodiol (Standard) is the analytical standard of (±)-Enterodiol. This product is intended for research and analytical applications. (±)-Enterodiol is the racemate of Enterodiol (HY-108695). Enterodiol is transformed by human intestinal bacteria from lignans contained in various whole-grain cereals, nuts, legumes, flaxseed, and vegetables. Enterodiol has an apoptotic effect in colorectal cancer (CRC) cells. Enterodiol has anti-cancer activities .
    (±)-Enterodiol (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: